APX-3330 is under clinical development by Apexian Pharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect APX-3330’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their APX-3330 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
APX-3330 is under development for the treatment of solid tumors including pancreatic ductal adenocarcinoma, pancreatic ductal adenocarcinoma, endometrial cancer, melanoma, chronic hepatitis C, prostate cancer and colorectal cancer, diabetic macular edema, non proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), hematological cancers including acute lymphoblastic leukemia, malignant peripheral nerve sheath tumor (MPNST), laser-induced choroidal neovascularization, tuberous sclerosis complex (TSC), inflammation, inflammatory bowel disease, wet age-related macular degeneration, gall bladder cancer, hepatocellular cancer, bladder cancer and ovarian cancer. It is a new chemical entity and is administered orally as a tablet. The drug candidate acts by targeting Ref-1 and TNF synthesis.
It was also under development for the treatment of hepatic failure and chemotherapy-induced peripheral neuropathy.
Apexian Pharmaceuticals overview
Apexian Pharmaceuticals is a clinical-stage biotechnology company.It develops and commercializes pharmaceuticals for the treatment of cancer and ocular diseases. The company is headquartered in Indianapolis, Indiana, United States.
Quick View APX-3330 LOA Data
|Highest Development Stage|